E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Children aged 24 months to (and including) 17 years with IgE-mediated food allergy to egg protein |
|
E.1.1.1 | Medical condition in easily understood language |
Children aged 24 months to (and including) 17 years with egg allergy |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10014315 |
E.1.2 | Term | Egg allergy |
E.1.2 | System Organ Class | 100000004870 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Is the administration of the intranasal LAIV influenza ('flu) vaccine safe in children with egg allergy? |
|
E.2.2 | Secondary objectives of the trial |
Is the administration of the intranasal LAIV influenza ('flu) vaccine safe in children who have experienced a previous severe allergic reaction (anaphylaxis) to egg? |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Aged 2 – 17 years old
2. Physician-diagnosis of egg allergy WITH current avoidance of egg in one of the following categories: • E0 – avoids all foods containing egg in any form • E1 – tolerates egg in baked foods (cakes, biscuits) but not other forms • E2 – able to eat lightly cooked egg (e.g. scrambled egg, boiled egg) but reacts to raw egg in uncooked cake mixtures, fresh mayonnaise, ice cream etc.
3. Written informed consent from parent/guardian (or the patient themselves from age 16 years), with assent from children aged 8 years and above wherever possible.
|
|
E.4 | Principal exclusion criteria |
1. Clinical resolution of egg allergy
2. Contraindications to LAIV (notwithstanding allergy to egg protein): a. Hypersensitivity to the active ingredients, gelatin or gentamicin (a possible trace residue) b. Previous systemic allergic reaction to LAIV c. Previous allergic reaction to an influenza vaccine (not LAIV) is a relative contra-indication, which must be discussed with the site PI to confirm patient suitability d. Children/adolescents who are clinically immunodeficient due to conditions or immunosuppressive therapy such as: acute and chronic leukaemias; lymphoma; symptomatic HIV infection; cellular immune deficiencies; and high-dose corticosteroids. NB: LAIV is not contraindicated for use in individuals with asymptomatic HIV infection; or individuals who are receiving topical/inhaled corticosteroids or low-dose systemic corticosteroids or those receiving corticosteroids as replacement therapy, e.g. for adrenal insufficiency. e. Children and adolescents younger than 18 years of age receiving salicylate therapy because of the association of Reye's syndrome with salicylates and wild-type influenza infection.
3. Contraindication to vaccination on that occasion, due to child being acutely unwell: a. Febrile ≥38.0oC in last 72 hours b. Acute wheeze in last 72 hours requiring treatment beyond that normally prescribed for regular use by the child’s treating healthcare professional c. Recent admission to hospital in last 2 weeks for acute asthma d. Current oral steroid for asthma exacerbation or course completed within last 2 weeks |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Immediate allergic reaction to Fluenz intranasal vaccination (onset of symptoms within 2 hours following administration). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Subjects will be observed for at least 30 minutes following administration of the vaccine. Follow-up interview (by telephone) at least 72hrs after vaccine dose. |
|
E.5.2 | Secondary end point(s) |
1. Delayed onset allergic reaction (within 72 hours following administration) 2. Adverse events (of non-allergic aetiology) following administration
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Delayed events will be assessed by telephone follow-up within 4-7 days of vaccination. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 32 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 28 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 28 |